News
**A New Dawn for Alzheimer’s Treatment: What Doctors and Patients Need to Know**
Hopes are high that donanemab will improve the quality of life for those in the early stages of Alzheimer’s.
The recent approval of donanemab (sold as Kisunla) by the Therapeutic Goods Administration (TGA) marks a pivotal moment in the fight against Alzheimer’s disease. This is the first new treatment of its kind in Australia in a quarter of a century, giving new hope to patients and their families. But what does this mean for patients, GPs, and the healthcare system as a whole?
Understanding Donanemab: How Does It Work?
Donanemab is designed to target and remove amyloid plaques from the brain, a hallmark of Alzheimer’s. The drug is approved for adults with early symptomatic Alzheimer’s disease who meet specific criteria, including a certain genetic profile and the presence of amyloid plaque confirmed by brain scans.
A phase three clinical trial, involving 1,736 participants, demonstrated that donanemab slowed cognitive and functional decline by up to 35% over 18 months compared to a placebo. This is a significant step forward in managing this devastating disease.
Challenges and Considerations for Patients
While the approval of donanemab is welcome news, several practical hurdles remain.
One of the main barriers is the cost. The private prescription price is approximately $4,700 per monthly infusion. It’s given for up to 18 months, creating a significant financial burden.
The good news? The drug’s manufacturer, Eli Lilly, has applied for donanemab to be included on the Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory Committee is scheduled to review this in July, and if approved, could substantially improve access.
Did you know? Alzheimer’s disease is the second leading cause of death in Australia and the leading cause of death for Australian women.
The Role of GPs and Early Detection
GPs play a crucial role in identifying and managing patients with early-stage Alzheimer’s. Donanemab is most effective when administered in the early stages of the disease, making early diagnosis critical. GPs are encouraged to be proactive in addressing any cognitive concerns.
Dr. Stephanie Daly, a GP with a special interest in dementia, highlights the importance of early intervention. “It’s exciting because there have been lots of other types of drugs like this which haven’t shown any benefit, and now this one has shown some benefit,” she told *newsGP*.
Pro tip: GPs should stay updated on the latest diagnostic tools and guidelines to identify early signs of mild cognitive impairment. Consider creating a referral pathway to specialists for timely assessment.
Potential Side Effects and Monitoring
Like all medications, donanemab comes with potential side effects. These include brain swelling and bleeding, which are more common in individuals carrying two copies of a specific gene variant (ApoE ε4), which increases the risk of Alzheimer’s.
Before starting donanemab, patients must undergo testing to determine their ApoE ε4 status. Regular MRIs are necessary to monitor for brain bleeding and swelling throughout treatment.
Looking Ahead: The Future of Alzheimer’s Treatment
The advent of donanemab signifies a new era in Alzheimer’s treatment. As more effective treatments become available, we can anticipate a greater emphasis on early detection and proactive care.
Research is ongoing, with scientists exploring new therapeutic approaches, including combination therapies and precision medicine strategies. The goal is to provide patients with personalized, effective treatment plans.
FAQ: Your Questions Answered
Q: Who is eligible for donanemab?
A: Adults with early symptomatic Alzheimer’s disease who have a specific genetic profile and confirmed amyloid plaque in the brain.
Q: What are the potential side effects?
A: Brain swelling and bleeding.
Q: How is donanemab administered?
A: Monthly infusions.
Q: Is it available on the PBS?
A: An application is under review, with a decision expected soon.
Alzheimer’s disease donanemab TGA Therapeutic Goods Administration
As a GP, do you use any resources or visit a healthcare professional to support your own mental health and wellbeing?
Are you a GP or a patient impacted by Alzheimer’s? Share your thoughts and experiences in the comments below. What do you think about the future of Alzheimer’s treatment?